Union Therapeutics recruits first psoriasis patient for phase IIb study
Biotech company Union Therapeutics is now testing its psoriasis treatment orismilast in an orally administered version. It is also testing the drug in a rare indication called hidradenitis suppurativa and atopic eczema.
by ulrich quistgaard, translated by catherine brett
Union Therapeutics is attempting to find the perfect dosage of drug candidate orismilast in a phase IIb study of psoriasis patients.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
